|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singer EA, Gupta GN, Marchalik D and
Srinivasan R: Evolving therapeutic targets in renal cell carcinoma.
Curr Opin Oncol. 25:273–280. 2013.PubMed/NCBI
|
|
3
|
Macher-Goeppinger S, Bermejo JL,
Schirmacher P, Pahernik S, Hohenfellner M and Roth W:
Senescence-associated protein p 400 is a prognostic marker in renal
cell carcinoma. Oncol Rep. 30:2245–2253. 2013.PubMed/NCBI
|
|
4
|
Tanaka T, Kuramitsu Y, Wang Y, et al:
Glyoxalase 1 as a candidate for indicating the metastatic potential
of SN12C human renal cell carcinoma cell clones. Oncol Rep.
30:2365–2370. 2013.PubMed/NCBI
|
|
5
|
Wei C, Lai YQ, Li XX and Ye JX:
TGF-β-activated kinase-1: a potential prognostic marker for clear
cell renal cell carcinoma. Asian Pac J Cancer Prev. 14:315–320.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iwamoto H, Kanda Y, Sejima T, Osaki M,
Okada F and Takenaka A: Serum miR-210 as a potential biomarker of
early clear cell renal cell carcinoma. Int J Oncol. 44:53–58.
2014.PubMed/NCBI
|
|
7
|
Pei L and Melmed S: Isolation and
characterization of a pituitary tumor-transforming gene (PTTG). Mol
Endocrinol. 11:433–441. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zou H, McGarry TJ, Bernal T and Kirschner
MW: Identification of a vertebrate sister-chromatid separation
inhibitor involved in transformation and tumorigenesis. Science.
285:418–422. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng ZZ, Chen JW, Yang ZR, Lu GZ and Cai
ZG: Expression of PTTG1 and PTEN in endometrial carcinoma:
correlation with tumorigenesis and progression. Med Oncol.
29:304–310. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoon CH, Kim MJ, Lee H, et al: PTTG1
oncogene promotes tumor malignancy via epithelial to mesenchymal
transition and expansion of cancer stem cell population. J Biol
Chem. 287:19516–19527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei C, Wu S, Li X, Wang Y, Ren R, Lai Y
and Ye J: High expression of FER tyrosine kinase predicts poor
prognosis in clear cell renal cell carcinoma. Oncol Lett.
5:473–478. 2013.PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2–ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Demeure MJ, Coan KE, Grant CS, et al:
PTTG1 overexpression in adrenocortical cancer is associated with
poor survival and represents a potential therapeutic target.
Surgery. 154:1405–1416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kakar SS and Jennes L: Molecular cloning
and characterization of the tumor transforming gene (TUTR1): a
novel gene in human tumorigenesis. Cytogenet Cell Genet.
84:211–216. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hamid T, Malik MT and Kakar SS: Ectopic
expression of PTTG1/securin promotes tumorigenesis in human
embryonic kidney cells. Mol Cancer. 4:32005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang SQ, Liao QJ, Wang XW, Xin DQ, Chen
SX, Wu QJ and Ye G: RNAi-mediated knockdown of pituitary
tumor-transforming gene-1 (PTTG1) suppresses the proliferation and
invasive potential of PC3 human prostate cancer cells. Braz J Med
Biol Res. 45:995–1001. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Caporali S, Alvino E, Levati L, et al:
Down-regulation of the PTTG1 proto-oncogene contributes to the
melanoma suppressive effects of the cyclin-dependent kinase
inhibitor PHA-848125. Biochem Pharmacol. 84:598–611. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Solbach C, Roller M, Peters S, Nicoletti
M, Kaufmann M and Knecht R: Pituitary tumor-transforming gene
(PTTG): a novel target for anti-tumor therapy. Anticancer Res.
25:121–125. 2005.PubMed/NCBI
|
|
20
|
Cho-Rok J, Yoo J, Jang YJ, et al:
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver
cancer cell growth in vitro and in vivo. Hepatology. 43:1042–1052.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsu YH, Liao LJ, Yu CH, et al:
Overexpression of the pituitary tumor transforming gene induces p
53-dependent senescence through activating DNA damage response
pathway in normal human fibroblasts. J Biol Chem. 285:22630–22638.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bernal JA, Luna R, Espina A, et al: Human
securin interacts with p 53 and modulates p 53-mediated
transcriptional activity and apoptosis. Nat Genet. 32:306–311.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang M, Chen X, Liu W, Li S, Li C, Jiang
L and Lv S: Role of the pituitary tumor transforming gene 1 in the
progression of hepatocellular carcinoma. Cancer Biol Ther.
11:337–345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levi F, Ferlay J, Galeone C, Lucchini F,
Negri E, Boyle P and La Vecchia C: The changing pattern of kidney
cancer incidence and mortality in Europe. BJU Int. 101:949–958.
2008. View Article : Google Scholar : PubMed/NCBI
|
